Lactobacillus rhamnosus GG improves outcome in experimental pseudomonas aeruginosa pneumonia: Potential role of regulatory T cells

Shock

Volumn 40, Issue 6, 2013, Pages 496-503

  Khailova, Ludmila ^a   Baird, Christine H ^a   Rush, Aubri A ^a   McNamee, Eoin N ^a   Wischmeyer, Paul E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Lactobacillus rhamnosus GG; lung injury; survival; Treg cells

Indexed keywords

GENTAMICIN; INTERLEUKIN 10; INTERLEUKIN 6; PROBIOTIC AGENT; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; BACTERIAL COUNT; BACTERIUM CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; FLOW CYTOMETRY; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS RHAMNOSUS GG; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; REGULATORY T LYMPHOCYTE; SURVIVAL;

ANIMALS; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; LACTOBACILLUS RHAMNOSUS; MICE; MICE, INBRED STRAINS; NEUTROPHIL INFILTRATION; PNEUMONIA, BACTERIAL; PROBIOTICS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RNA, MESSENGER; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84888086107     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000066     Document Type: Conference Paper

References (37)

1. Heron M: Deaths: leading causes for 2008. Natl Vital Stat Rep 60(6):1-94, 2012.
2. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, et al: International study of the prevalence and outcomes of infection in intensive care units. JAMA 302(21):2323-2329, 2009.
3. Rello J, Ausina V, Ricart M, Castella J, Prats G: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104(4):1230-1235, 1993.
4. Kollef MH: What is ventilator-associated pneumonia and why is it important? Respir Care 50(6):714-721, 2005; discussion 714-721.
5. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Gensini GF, Gusinu R: Antibiotic prophylaxis to prevent nosocomial infections in patients in intensive care units: evidence that struggle to convince practising clinicians. Intern Emerg Med 1(2):160-162, 2006.
6. Hojsak I, Abdovic S, Szajewska H, Milosevic M, Krznaric Z, Kolacek S: Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 125(5):e1171Ye1177, 2010.
7. Morrow LE, Kollef MH, Casale TB: Probiotic prophylaxis of ventilatorassociated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 182(8):1058-1064, 2010.
8. Petrof EO, Dhaliwal R, Manzanares W, Johnstone J, Cook D, Heyland DK: Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med 40(12):3290-3302, 2012.
9. Hammerman C, Bin-Nun A, Kaplan M: Germ warfare: probiotics in defense of the premature gut. Clin Perinatol 31(3):489-500, 2004.
10. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P: A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 32(2):147-152, 2008.
11. Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, Isolauri E: Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 104(5):e64, 1999.
12. Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, De Champs C: Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit Care 12(3):R69, 2008.
13. Giamarellos-Bourboulis EJ, Bengmark S, Kanellakopoulou K, Kotzampassi K: Pro-and synbiotics to control inflammation and infection in patients with multiple injuries. J Trauma 67(4):815-821, 2009.
14. Shanahan F: Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr 88(Suppl 1):S5YS9, 2002.
15. Khailova L, Frank DN, Dominguez JA, Wischmeyer PE: Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. Anesthesiology 119:166-177, 2013.
16. Aguero G, Villena J, Racedo S, Haro C, Alvarez S: Beneficial immunomodulatory activity of Lactobacillus casei in malnourished mice pneumonia: effect on inflammation and coagulation. Nutrition 22(7-8):810-819, 2006.
17. Matsumoto T, Ishikawa H, Tateda K, Yaeshima T, Ishibashi N, Yamaguchi K: Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice. J Appl Microbiol 104(3):672-680, 2008.
18. Zareie M, Johnson-Henry K, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM: Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 55(11):1553-1560, 2006.
19. Khailova L, Mount Patrick SK, Arganbright KM, Halpern MD, Kinouchi T, Dvorak B: Bifidobacterium bifidum reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 299(5):G1118YG1127, 2010.
20. O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, et al: Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog 4(8):e1000112, 2008.
21. Konieczna P, Groeger D, Ziegler M, Frei R, Ferstl R, Shanahan F, Quigley EM, Kiely B, Akdis CA, O'Mahony L: Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 61(3):354-366, 2012.
22. Neill DR, Fernandes VE, Wisby L, Haynes AR, Ferreira DM, Laher A, Strickland N, Gordon SB, Denny P, Kadioglu A, et al. : T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathogens 8(4):e1002660, 2012.
23. Robertson CM, Perrone EE, McConnell KW, Dunne WM, Boody B, Brahmbhatt T, Diacovo MJ, van Rooijen N, Hogue LA, Cannon CL, et al: Neutrophil depletion causes a fatal defect in murine pulmonary Staphylococcus aureus clearance. J Surg Res 150(2):278-285, 2008.
24. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using realtime quantitative PCR and the 2(-delta delta C(T)) method. Methods 25(4): 402-408, 2001.
25. Alverdy JC, Chang EB: The re-emerging role of the intestinal microflora in critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not go away. J Leukoc Biol 83(3):461-466, 2008.
26. Alberda C, Gramlich L, Meddings J, Field C, McCargar L, Kutsogiannis D, Fedorak R, Madsen K: Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 85(3): 816-823, 2007.
27. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF: Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 82(2):103-108, 2002.
28. McNaught CE, Woodcock NP, Anderson AD, MacFie J: A prospective randomised trial of probiotics in critically ill patients. Clin Nutr 24(2):211-219, 2005.
29. Honeycutt TC, El Khashab M, Wardrop RM 3rd, McNeal-Trice K, Honeycutt AL, Christy CG, Mistry K, Harris BD, Meliones JN, Kocis KC: Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med 8(5): 452-458, 2007; quiz 464.
30. Rivas MN, Koh YT, Chen A, Nguyen A, Lee YH, Lawson G, Chatila TA: MyD88 is critically involved in immune tolerance breakdown at environmental interfaces of Foxp3-deficient mice. J Clin Invest 122(5):1933-1947, 2012.
31. Blair C, Naclerio RM, Yu X, Thompson K, Sperling A: Role of type 1 T helper cells in the resolution of acute Streptococcus pneumoniae sinusitis: a mouse model. J Infect Dis 192(7):1237-1244, 2005.
32. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 4(4):330-336, 2003.
33. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, Zaat BA, Yazdanbakhsh M, Wierenga EA, van Kooyk Y, et al: Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cellYspecific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 115(6): 1260-1267, 2005.
34. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M: Probiotic administration in patients with ileal pouchanal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14(5):662-668, 2008.
35. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JNV, Suttorp MJ, Johnsen B, Shanman R, Slusser W, Fu N, et al. Safety of probiotics to reduce risk and prevent or treat disease. Evidence report/technology assessment no. 200. AHRQ publication 11-E007 2011.
36. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, et al: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371(9613):651-659, 2008.
37. Morrow LE, Gogineni V, Malesker MA: Synbiotics and probiotics in the critically ill after the PROPATRIA trial. Curr Opin Clin Nutr Metab Care 15(2):147-150, 2012.